Cargando…
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
p53, encoded by the tumor suppressor gene TP53, is one of the most important tumor suppressor factors in vivo and can be negatively regulated by MDM2 through p53–MDM2 negative feedback loop. Abnormal p53 can be observed in almost all tumors, mainly including p53 mutation and functional inactivation....
Autores principales: | Zhu, Haohao, Gao, Hui, Ji, Yingying, Zhou, Qin, Du, Zhiqiang, Tian, Lin, Jiang, Ying, Yao, Kun, Zhou, Zhenhe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277894/ https://www.ncbi.nlm.nih.gov/pubmed/35831864 http://dx.doi.org/10.1186/s13045-022-01314-3 |
Ejemplares similares
-
Small-Molecule Inhibitors
of the MDM2–p53 Protein–Protein
Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment: Miniperspective
por: Zhao, Yujun, et al.
Publicado: (2014) -
Recent Small-Molecule Inhibitors of the p53–MDM2 Protein–Protein Interaction
por: Beloglazkina, Anastasia, et al.
Publicado: (2020) -
The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2019) -
Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors
por: Cheng, Xiyao, et al.
Publicado: (2022) -
Fortifying p53 – beyond Mdm2 inhibitors
por: Sriraman, Anusha, et al.
Publicado: (2016)